Filing Details

Accession Number:
0001179110-19-001904
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-02-14 16:26:34
Reporting Period:
2019-02-12
Accepted Time:
2019-02-14 16:26:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1235010 Momenta Pharmaceuticals Inc MNTA Biological Products, (No Disgnostic Substances) (2836) 043561634
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1706857 Santiago Arroyo C/O Momenta Pharmaceuticals, Inc.
301 Binney Street
Cambridge MA 02142
Svp, Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-02-12 25,000 $0.00 58,335 No 4 M Direct
Common Stock Disposition 2019-02-13 7,742 $12.70 50,593 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2019-02-12 25,000 $0.00 25,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
25,000 No 4 M Direct
Footnotes
  1. Shares received pursuant to settlement of Restricted Stock Units that were granted on February 12, 2018.
  2. This transaction was effected pursuant to a Rule 10b5-1 trading plan.
  3. Restricted Stock Units convert into common stock on a one-for-one basis.
  4. Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 50% of the shares on the first anniversary of the grant date, and the remaining 50% will vest on the second anniversary of the grant date.